BG-8
BG-8 is a monoclonal antibody that recognises the blood group Lewisy.
Immunohistochemical expression
Diagnostic utility
|
|
adenocarcinoma
|
mesothelioma
|
|
Jordan 19891
|
18/18(pulmonary adenocarcinomas)
|
7/30
|
|
Battifora 19952
|
108/125(various sites of origin; staining was stronger than in the positive mesotheliomas)
|
10/100(epithelial or biphasic mesotheliomas)
|
|
Riera 19973
|
187/211(various sites of origin)
|
5/57
|
|
Wilson 19974
|
9/9(pulmonary and ovarian carcinomas)
|
5/21
|
|
Ordonez 20005
|
114/135(39/40 lung, 25/25 breast, 26/30 ovary, 9/10 colon, 1/10 kidney, 6/10 thyroid, 8/10 prostate)
|
3/50
|
|
Ordonez 20036
|
48/50(all primary lung adenocarcinomas: 21 case >75% of cells stained, 15 cases 50-75% of cells, 7 cases 25-50% of cells, 6 cases 1-25% of cells and 1 cases <1% of cells. Staining cytoplasmic and membranous)
|
4/60(all epithelioid mesotheliomas: 2 cases 1-25% of cells and 2 cases <1% of cells.)
|
|
Overall
|
88% (484/548)
|
11% (34/318)
|
A systematic review of three studies (consisting of 231 pulmonary adenocarcinomas and 197 epithelioid mesotheliomas) reported sensitivities and specificities of BerEP4 for pulmonary adenocarcinoma of 93% and 93%7.
References
1 Jordan D, Jagirdar J, Kaneko M. Blood group antigens, Lewisx and Lewisy in the diagnostic discrimination of malignant mesothelioma versus adenocarcinoma. Am J Pathol 1989;135:931-7.
2 Battifora H. Diffuse malignant mesothelioma. In Battifora H, McCaughey WTE, eds. Atlas of Tumor Pathology: Tumors of the serosal membranes, page 71, 3rd series fascicle 15, AFIP.
3 Riera, J. R., C. Astengo-Osuna, et al. (1997). "The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval [see comments]." Am J Surg Pathol 21(12): 1409-19.
4 Wilson JD, Merino MJ, Harris C et al. Mesothelioma vs adenocarcinma: does immunohsitochemsitry help? Lab Invest 1997;76:174A.
5 Ordonez, N. G. (2000). "Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma." Am J Surg Pathol 24(4): 598-606.
6 Ordonez, N. G. (2003). "The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma." Am J Surg Pathol 27(8): 1031-51.
7 King JE, Thatcher N, Pickering CA, et al. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. Histopathology 2006; 48:223-32
This page last revised 16.2.2006.
©SMUHT/PW Bishop